Nebivolol
Bystolic
Nebivolol (Bystolic) is a longevity & bioregulators research compound. Highly beta-1 selective blocker that also stimulates nitric-oxide-mediated vasodilation — the only beta blocker with that second mechanism.
Nebivolol quick facts
| Reported research dose | 2.5–10mg daily |
| Route | Oral |
| Frequency | 1x |
| Half-life | ~10 hours (longer in poor CYP2D6 metabolizers) |
| Forms | Oral |
| Evidence level | Approved for hypertension; the favorable metabolic profile rests on smaller trials |
The beta blocker least likely to cause the classic complaints — fatigue, erectile dysfunction, worsened lipids and insulin resistance — because of the NO-mediated vasodilation and the beta-1 selectivity. If a beta blocker is needed in someone who trains, this is usually the one.
How Nebivolol works
Highly beta-1 selective blocker that also stimulates nitric-oxide-mediated vasodilation — the only beta blocker with that second mechanism.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Nebivolol
Buy Nebivolol at AlgoRx →The evidence for Nebivolol
Graded by what exists behind each claim.
✅ Clinically validated
- Approved for hypertension, with the SENIORS trial (2,128 patients over 70) showing reduced death and cardiovascular hospitalization in elderly heart failure patients — notably including those with preserved ejection fraction, a group where little else has worked.
- Head-to-head hard-outcome superiority over older beta-blockers has not been demonstrated, despite the favorable mechanism. The metabolic and vasodilatory advantages are real on measurement and unproven on events.
📊 Correlative data
- Widely prescribed, and the beta-blocker most often chosen when the conventional ones cause problems. Less fatigue, less erectile dysfunction and less metabolic disturbance are the consistent real-world reports.
🧪 Theoretical / extrapolated
- The most beta-1 selective beta-blocker available, and it does something no other one does: it stimulates endothelial nitric oxide release through beta-3 activation, producing vasodilation.
- That combination inverts the usual beta-blocker problem. Conventional beta-blockers raise peripheral resistance and worsen insulin sensitivity; adding NO-mediated vasodilation counteracts both.
- High beta-1 selectivity also means minimal beta-2 blockade — the mechanism behind less bronchospasm and less interference with fat mobilization during training.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Nebivolol actually does
Nebivolol is sold as one drug and is actually a 50:50 mixture of two molecules that do different things, and almost nothing written for patients says so. It is a racemate of d-nebivolol and l-nebivolol. The d-enantiomer carries essentially all of the beta-1 adrenoceptor blockade — and it is the most beta-1-selective blocker in clinical use, with a selectivity ratio over beta-2 far above metoprolol's or bisoprolol's, which is why airway and peripheral vascular effects are comparatively mild. The l-enantiomer has almost no beta-1 activity and is the half associated with the nitric-oxide-mediated vasodilation. One tablet, two pharmacologies.
The vasodilator half is where the argument is, and the candidate receptor is beta-3. Beta-3 adrenoceptors on vascular endothelium couple to endothelial nitric oxide synthase; agonism there raises NO, which diffuses to smooth muscle, activates soluble guanylate cyclase, raises cyclic GMP and relaxes the vessel Dongdem 2024. That is the same receptor mirabegron targets in the bladder and the same receptor the beiging literature in this Vault is built on — so nebivolol is a beta-blocker with a beta-3 story, which is why it does not behave like the rest of its class.
And the NO claim is not inferred. It was measured in a randomized human crossover. In hypertensive men, plasma nitric oxide increased on nebivolol (p<0.001) and did not on metoprolol (p=0.268), and the change correlated with sexual function scores (r=0.284, p=0.026) Gungor 2022. That is receptor pharmacology producing a measured mediator producing a measured endpoint, in one trial, in people.
Why a vasodilating beta-blocker should have a different metabolic profile. Classical beta-blockade reduces cardiac output and, through unopposed alpha-1 tone, raises peripheral resistance; reduced skeletal muscle perfusion means less glucose delivery to the tissue that disposes of most of it, and beta-2 blockade impairs lipolysis and insulin secretion. A drug that lowers blood pressure by dilating rather than only by slowing preserves muscle perfusion — which is the mechanistic reason to expect a better lipid and glucose profile, and the reason the metabolic claims for this drug are a prediction from mechanism rather than a marketing line.
Cell, rodent, human — and where it stops
Step one, in humans, on the metabolic claim — and the numbers are modest and real. A systematic review and meta-analysis of 1,456 patients across 12 randomized trials compared nebivolol against other beta-blockers in essential hypertension. Blood pressure lowering was not superior (weighted mean difference for systolic -0.57 mmHg, 95% CI -1.55 to 0.42, p=0.12). But the lipid profile was better: LDL cholesterol lower by 8.88 mg/dL and HDL cholesterol higher by 2.30 mg/dL Wikananda 2024. Read that carefully, because it is the honest shape of the claim: nebivolol is not a better antihypertensive. It is a beta-blocker with less metabolic cost.
Step two, on the endpoint people actually change drugs for. A prospective, randomized, crossover trial in hypertensive men with erectile dysfunction compared nebivolol against metoprolol. Antihypertensive efficacy was equivalent (p=0.828). Metoprolol significantly decreased IIEF-5 scores (p<0.001 for the psychogenic subgroup); nebivolol did not (p=0.201), and plasma nitric oxide rose only on nebivolol Gungor 2022. Same blood pressure, different sexual function outcome, with a measured mediator in between — which is as clean a receptor-to-endpoint chain as this class produces.
Step three, the obstacle, and it is pharmacogenetic. Nebivolol is metabolized by CYP2D6, and CYP2D6 activity varies enormously between people by genotype. The Clinical Pharmacogenetics Implementation Consortium now publishes a guideline covering CYP2D6 together with the adrenoceptor and kinase genotypes for beta-blocker therapy Duarte 2024, and modeling work addresses exposure and dosage regimen directly Marques 2022. The consequence is that ‘5 mg of nebivolol’ is not one exposure — it is a several-fold range depending on a gene nobody has tested, and the same range can be produced by a drug somebody is already taking.
Nebivolol pharmacokinetics — how much of it actually gets in
The card says ~10 hours, longer in poor CYP2D6 metabolizers. That parenthesis is the most consequential clause on the card and it deserves the arithmetic.
What degrades it. Nebivolol is cleared by CYP2D6, by aromatic hydroxylation and N-dealkylation, followed by glucuronidation of both parent and metabolites. Some of the hydroxylated metabolites retain beta-blocking activity, so the pharmacodynamic effect outlasts the parent's plasma curve — which is why once-daily dosing works for a drug with a nominal ten-hour half-life.
The number the parenthesis is hiding. In extensive metabolizers the half-life is roughly 10 hours. In poor metabolizers it is on the order of 30–50 hours, with systemic exposure several-fold higher on the same milligrams Marques 2022. That is not a footnote — it is the difference between a once-daily drug and a drug that accumulates for a week before it reaches steady state. Roughly 5–10% of people of European ancestry are poor metabolizers, and the distribution differs substantially by ancestry, which is why the guideline exists Duarte 2024.
And a genotype is not required to create a poor metabolizer. Strong CYP2D6 inhibitors — paroxetine, fluoxetine, bupropion, quinidine, terbinafine, duloxetine — convert a normal metabolizer into a functional poor one. The clinical consequence has now been measured: in a register-based case-crossover study, concomitant use of CYP2D6-inhibiting drugs with newly initiated beta-blockers raised the risk of fall injury with an odds ratio of 1.37 (1.24–1.52) overall, rising to 2.25 (1.39–3.63) with strong inhibitors Leander 2025. Starting an antidepressant and a beta-blocker in the same month is an ordinary clinical event with a measured consequence.
The oral barrier. Oral bioavailability is roughly 12–30% in extensive metabolizers and around 96% in poor metabolizers — almost the entire difference is first-pass metabolism by CYP2D6 in the liver. That is why the exposure ratio between phenotypes is so large: the enzyme is removing most of the dose before it reaches the circulation in one group and almost none in the other. There is no injectable form and none is needed; the issue is not absorption but what happens immediately after it.
What would have to be true, and how you would know it was not
Three predictions with markers, directions and windows. The third is the one that argues against assuming this drug is metabolically free.
1. The lipid panel should hold or improve, which is the whole reason to choose this molecule over another beta-blocker. Order a lipid panel and ApoB at baseline and at 12 weeks. Prediction from the meta-analysis: LDL roughly 9 mg/dL lower and HDL roughly 2 mg/dL higher than would be expected on a conventional beta-blocker Wikananda 2024. That is a small effect, and it is the correct size to expect — a page that promised more would be overselling a real but modest advantage.
2. Fasting insulin and HbA1c should not deteriorate, and that is the falsifiable version of the metabolic claim. Conventional beta-blockade worsens insulin sensitivity through reduced muscle perfusion and beta-2 blockade. Draw fasting insulin and HbA1c at baseline and 6 months. Prediction: flat. If either drifts up, the vasodilator arm is not compensating in that person, and the whole argument for choosing this drug over a cheaper one has failed for them specifically.
3. The prediction that cuts against it: resting heart rate is the exposure assay, and a very low one means a CYP2D6 problem. Beta-1 blockade lowers heart rate in proportion to exposure, so resting heart rate is a free, continuous, at-home readout of a pharmacokinetic variable nobody genotypes. Record it every morning for two weeks before starting and for six weeks after. Prediction: a poor metabolizer, or anyone on a strong CYP2D6 inhibitor, will show a disproportionate fall and reach steady state days later than expected Marques 2022 Duarte 2024. That matters because the measured harm in this interaction is falls Leander 2025, and an unexpectedly low heart rate is the warning that arrives before the fall does.
What nobody has tested yet
Four questions this drug has not answered in twenty years on the market.
Nobody has run a hard-outcome trial of nebivolol against another beta-blocker. The lipid and sexual-function advantages are real and measured Wikananda 2024 Gungor 2022; whether they translate into fewer cardiovascular events has never been tested head to head, and it is the question a prescriber actually needs answered.
Nobody has tested CYP2D6-guided dosing prospectively for this drug. The guideline exists Duarte 2024, the exposure difference is several-fold, and the harm signal from the interaction has been quantified Leander 2025. Whether genotyping before starting reduces adverse events is a trial nobody has run, on a generic drug with no sponsor.
Nobody has separated the two enantiomers in a clinical trial. If the l-enantiomer carries the nitric oxide effect with almost no beta-1 blockade, it is in principle a vasodilator without the bradycardia. That single-enantiomer comparison has never been made in people, and it would settle whether the vasodilation is worth having on its own.
Nobody has looked for the beta-3 metabolic effect in humans. Beta-3 agonism is the mechanism behind the adipose beiging literature Dongdem 2024, and nebivolol's vasodilation is attributed to that receptor. Whether chronic nebivolol produces any measurable change in resting energy expenditure or in adipose gene expression is an obvious question, given that another beta-3 agonist in this Vault is studied for exactly that, and nobody has asked it.
Nebivolol — its own safety story, not its class's
This drug's specific risks are a pharmacogenetic one, a withdrawal one and an airway one, and only the last is shared with the class block below.
The CYP2D6 interaction is the specific hazard, and its consequence has been counted. Concomitant CYP2D6 inhibitors with a newly started beta-blocker raised fall-injury risk with an odds ratio of 1.37, and 2.25 with strong inhibitors; notably the elevation was similar regardless of how CYP2D6-dependent the particular beta-blocker was Leander 2025. The inhibitors in question are common antidepressants. The practical measure is not a genotype test most people will not get — it is knowing that starting paroxetine, fluoxetine or bupropion alongside this drug changes its exposure, and watching resting heart rate and standing blood pressure for two weeks afterwards.
Abrupt discontinuation is the class's most under-respected risk and it is a receptor effect. Chronic beta blockade upregulates beta-adrenoceptor density; stopping suddenly exposes an increased receptor population to normal catecholamine levels, producing rebound tachycardia, hypertension and, in people with coronary disease, ischemia. This is the one situation in which running out of a medication is genuinely more dangerous than never having started it, and it argues for tapering over one to two weeks rather than stopping.
The airway question, in proportion. Nebivolol is the most beta-1-selective agent in the class, so it is the one least likely to provoke bronchospasm — but selectivity is relative and it declines as the dose rises, which is exactly what happens in a poor metabolizer at a standard dose. Asthma is a conversation with a prescriber, not a calculation from a web page.
And the masking effect that matters to this Vault's readers specifically. Beta blockade blunts the adrenergic warning signs of hypoglycemia — tremor and palpitations — while leaving sweating intact. In a population that also runs GLP-1 agonists, fasted training and, on other pages of this site, insulin-like compounds, that is a real interaction between pages rather than between molecules. Nebivolol is a prescription medicine and nothing here is medical advice or a recommendation for use.
Sources read for this page
- Duarte JD, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Clinical Pharmacology and Therapeutics 2024 · PMID 38951961
- Marques L, et al. New Data for Nebivolol after In Silico PK Study: Focus on Young Patients and Dosage Regimen. Pharmaceutics 2022 · PMID 36145659
- Gungor G, et al. Nebivolol protects erectile functions compared to Metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: A prospective, randomized, cross-over, clinical trial. European Journal of Internal Medicine 2022 · PMID 35752527
- Wikananda IMF, et al. Effects of Nebivolol therapy on hemodynamic parameters and lipid profile compared to other beta blockers in patients with essential hypertension: a systematic review and meta-analysis. Caspian Journal of Internal Medicine 2024 · PMID 38463918
- Dongdem JT, et al. The beta3-Adrenergic Receptor: Structure, Physiopathology of Disease, and Emerging Therapeutic Potential. Advances in Pharmacological and Pharmaceutical Sciences 2024 · PMID 39640497
- Leander K, et al. CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers: a register-based case-crossover study. Scientific Reports 2025 · PMID 40640338
Nebivolol — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- Highly beta-1 selective blockade slows heart rate and reduces contractility; the second mechanism — nitric-oxide-mediated vasodilation — is unique to this molecule in the class and is why it lowers peripheral resistance rather than raising it.
- The predicted consequences are the class's: bradycardia, fatigue, reduced peak exercise heart rate, and a blunted symptomatic warning of hypoglycemia. Beta-1 selectivity reduces but does not eliminate the bronchospasm risk, and selectivity falls as the dose rises.
- For anyone training, the relevant prediction is the ceiling on heart rate. Beta blockade caps the achievable rate, which changes what heart-rate-based training zones mean and reduces maximal aerobic output.
What has actually been reported
- Fatigue, dizziness and headache are the common complaints. Bradycardia is expected and is only a problem when symptomatic.
- Compared with older beta blockers, metabolic and lipid effects are smaller and erectile dysfunction is less frequent — the NO arm is the usual explanation, and it is the reason this one gets chosen.
- Abrupt withdrawal causes rebound tachycardia, hypertension and, in people with coronary disease, ischemia. This is the most important observed effect on the card because it is caused by stopping rather than starting.
How to reduce the risk
Same mechanism as the prediction.
- Never stop it abruptly. Taper over at least a week or two, with advice. The rebound is the dangerous part of this drug.
- Recalibrate training by rate of perceived exertion or power, not heart rate — your zones are no longer describing the same effort.
- Take it at night if fatigue is the limiting complaint.
What it does to your bloodwork
A fact about the assay.
- Blood pressure and resting heart rate matter more than any blood test here, and both need measuring at home rather than once a year.
- Fasting glucose and HbA1c — the metabolic effect is smaller than with older beta blockers, not absent.
- A lipid panel, for the same reason.
What it overlaps with
- With verapamil or diltiazem, the effects on conduction add and the combination can produce serious bradycardia or block.
- Beta blockade masks the adrenergic warning signs of hypoglycemia — relevant with insulin, a sulfonylurea, or a hard fast.
Don't run this if
- Severe bradycardia, second- or third-degree heart block, or sick sinus syndrome without a pacemaker.
- Decompensated heart failure, severe hepatic impairment.
- Asthma — beta-1 selectivity is relative, not absolute, and it degrades at higher doses.
The honest unknown
- There is no longevity outcome evidence for beta blockade in people without cardiovascular indication. The interest is extrapolated from blood pressure and heart-rate reduction as risk factors, which is a mechanism argument rather than a trial result.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Nebivolol — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Nebivolol moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Potassium and creatinine are the two that matter, and a CMP has both. ACE inhibitors and ARBs raise potassium by reducing aldosterone, and they cause a small expected rise in creatinine when started — a rise under about 30% is hemodynamic and is not kidney damage.
What to do: Baseline, then again 1–2 weeks after starting or after any dose increase. That second draw is the one people skip and it is the one that matters. - Cystatin C with eGFR — ◆ worth watching
A better read of kidney filtration than creatinine if you carry a lot of muscle — creatinine-based eGFR reads falsely low on a muscular person and turns a normal kidney into a scary number.
What to do: Worth one measurement if creatinine-based eGFR looks borderline and you train hard. - Uric Acid — ↓ expected to fall
Losartan specifically is uricosuric — it lowers uric acid, which is a genuine and under-used advantage if gout is in the picture. This is NOT a class effect; the other ARBs do not do it.
What to do: Relevant only if you have gout or a high baseline urate.
Beta-blockers are a different mechanism to the two above and carry their own specific caution: never stop one abruptly. Rebound tachycardia and hypertension are well documented. They also blunt the adrenaline response, which masks the early warning signs of hypoglycemia and flattens the training heart-rate response.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Nebivolol in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Nebivolol
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Nebivolol — frequently asked questions
What is Nebivolol?
Nebivolol (Bystolic) is a longevity & bioregulators research compound. Highly beta-1 selective blocker that also stimulates nitric-oxide-mediated vasodilation — the only beta blocker with that second mechanism.
Is the full Nebivolol protocol on this page?
The reported research dose is on this page, along with how Nebivolol works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Nebivolol?
Nebivolol has an approximate half-life of ~10 hours (longer in poor CYP2D6 metabolizers), which is part of what determines how often it's dosed.
What's the evidence behind Nebivolol?
Current evidence level: Approved for hypertension; the favorable metabolic profile rests on smaller trials. Nebivolol is offered for research purposes only and is not an approved medicine.
Nebivolol inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Nebivolol is used for
Nebivolol appears under 3 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Nebivolol is the endothelial arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.